C-Suite Speaks
CHARM Therapeutics' CEO discusses its DragonFold technology, applying AI to cancer drug hunting, and the benefits of its Nobel Prize-winning roots.
One month after announcing a pipeline pivot, Ovid Therapeutics talked to In Vivo about the importance of making strategic decisions with discipline, and the imminent neurology revolution.
Overseeing the diverse EMEA region as the regional president of Johnson & Johnson’s Vision business has been a whirlwind of activity for Jacqueline Henderson, in her role since 2023. Fresh back from the ESCRS 2024 meeting, she spoke to In Vivo about how J&J responds to market needs.
Attrition among biotechs and VCs holding onto their reserve capital for existing investments may have reduced the capital available for new life sciences funding, but UK-based LifeArc Ventures believes its recent activity is indicative of a general upswing.
The Chinese company is building on its success with ivonescimab and believes it can stay ahead of its rivals and develop into a global company.
Regeneron’s clinical and commercial oncology leaders talk to In Vivo about making good on the company’s oncology strategy and pushing the commercial accelerator in a post-Sanofi world.
Schrödinger has for years discovered drug candidates for other companies and derisked them, testing them in silico using its computational models. Now, it is exploring its own ability to develop drugs in the clinic, starting with low-risk bets. Will the company’s approach succeed where others have failed?
Ipsen rare diseases head Jennifer Schranz talks to In Vivo about why women are especially susceptible to a “diagnostic odyssey,” and how the company is working to find and treat female zebras.
Fusion Pharmaceuticals Inc CEO John Valliant talked to In Vivo about Canadian leadership in radiopharmaceutical innovation, its differentiated approach, and excitement around combination therapies for precision cancer treatments.
Patrick Alexandre, Crossject CEO, discusses crucial developments happening for Zeneo, a needle-free injector, functioning intramuscularly to administer medication in a tenth of a second
The potential of the UK’s life sciences sector continues to be critically misunderstood and should be the cornerstone of both society and the economy, according to Teva’s CEO Richard Francis.
Punit Dhillon, CEO of Skye Bioscience, tells In Vivo about the advancement of nimacimab as a weight loss mechanism within the growing space of anti-obesity therapeutics
John Lepore, CEO of ProFound Therapeutics and CEO-partner at Flagship Pioneering, discusses the vast possibilities for the human atlas, the benefits of strategic partnering and knowing when to walk away from a project.
Parexel’s chief strategy officer Kushal Gohil, clinical EVP Stephen Pyke and India head Sanjay Vyas share thoughts on possible hurdles to, and the cascading impact of obesity treatments, GenAI progress and the opportunities and challenges of real-world data in India.
In Vivo sat down with Benjamin Hadida, CEO of Exeliom, at the 2024 BIO International Convention to discuss how the company is using its first-in-class drug candidate to improve therapeutic responsiveness in immuno-oncology, immuno-inflammation and rare disease.
Stefan Woxström, senior vice president of AstraZeneca, Europe and Canada, discusses the growing challenges in the industry and addresses the role big pharma must adopt in resolving them.
Increased R&D spending, program acquisitions and a soaring headcount – Regeneron has seen significant growth over the past 5 years. The company is focused on marrying its antibody technologies with its expanding cell and gene therapy pipeline.
Key insights from the recent the BIO International Convention in San Diego, US.
Astellas Pharma’s chief commercial officer discusses the biopharma industry’s responsibility to drive change in health care.
Rezo’s chief technology officer Sourav Bandyopadhyay discusses the company's focus on leveraging AI and machine learning to accelerate drug discovery and its potential for partnerships with big pharma.